BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Solve ME/CFS Initiative - ECPv6.15.17//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Solve ME/CFS Initiative
X-ORIGINAL-URL:https://solvecfs.org
X-WR-CALDESC:Events for Solve ME/CFS Initiative
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20210314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20211107T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20220313T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20221106T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20230312T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20231105T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20240310T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20241103T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20260308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20261101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20270314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20271107T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Asia/Shanghai
BEGIN:STANDARD
TZOFFSETFROM:+0800
TZOFFSETTO:+0800
TZNAME:CST
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260714T150000
DTEND;TZID=America/Los_Angeles:20260714T160000
DTSTAMP:20260715T182111
CREATED:20260622T155750Z
LAST-MODIFIED:20260622T155750Z
UID:44319-1784041200-1784044800@solvecfs.org
SUMMARY:Repurposing Rapamycin: A Report On the First Biomarker-Driven Treatment Trial for ME/CFS
DESCRIPTION:In 2025\, Simmaron Research was the second recipient of Solve’s ME/CFS Catalyst Award in support of its study\, “Low Dose Rapamycin in ME/CFS\, Long-COVID\, and Other Infection-Associated Chronic Conditions.” The study hypothesizes that mTOR inhibition through rapamycin may address observed findings of autophagy impairment and symptoms in a subset of patients with ME/CFS and other infection-associated chronic conditions and illnesses (IACCIs).   \nThe study advances an already FDA-approved drug for reducing key symptoms of ME/CFS and Long Covid\, repurposing rapamycin to reduce fatigue\, orthostatic intolerance\, post-exertional malaise\, and sleep issues for a subset of people with ME/CFS. \nIn this webinar hosted by Solve M.E. President Emily Taylor\, panelists Courtney Miller (Board President at Simmaron)\, Dr. C. Gunnar Gottschalk (Chief Executive Officer at Simmaron)\, and Dr. Avik Roy (Chief Scientific Officer at Simmaron) will discuss the latest learnings from the study\, and their plan to conduct an  NIH exploratory treatment trial based on the data. 
URL:https://solvecfs.org/event/repurposing-rapamycin-a-report-on-the-first-biomarker-driven-treatment-trial-for-me-cfs/
CATEGORIES:Long Covid,Research,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2026/06/July14SimmaronWebinar2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260610T110000
DTEND;TZID=America/Los_Angeles:20260610T120000
DTSTAMP:20260715T182111
CREATED:20260512T140632Z
LAST-MODIFIED:20260512T140632Z
UID:43930-1781089200-1781092800@solvecfs.org
SUMMARY:Sequence ME & Long Covid: The Search for ME/CFS and Long Covid Biomarkers and Subtypes
DESCRIPTION:The DecodeME Project is the largest genetic study of ME/CFS conducted to date and has identified eight genetic signals where people with ME/CFS tend to differ from those without\, linked to the immune and nervous systems. These landmark findings reflect the lived experience of thousands of people with ME/CFS\, providing validation and exciting new avenues for research. \nIn earlier work\, the DecodeME team analyzed the genomes of 15\,500 people with ME/CFS\, finding critical genomic spots where variation significantly influences disease risk. Now\, with support from a Solve ME/CFS Catalyst Award\, the team will set up this ambitious project\, allowing them later to read these genomes in even more detail. \nWhile the earlier DecodeME study used technology that examined only a million genomic spots per participant\, the wider project will leverage Oxford Nanopore Technology’s new whole genome sequencing method to examine all three billion spots across the genome for most participants (9\,000 of the original 15\,500 participants). \nIn this free educational webinar\, host Dr. Jessica Maya (Solve Vice President of Scientific Programs) will talk to the DecodeME management team and recent Catalyst Award honorees Prof. Chris Ponting (Chair of Medical Bioinformatics\, University of Edinburgh)\, Sonya Chowdhury (Chief Executive\, Action For ME) and Andy Devereux-Cooke (Patient Representative and Co-Investigator at DecodeME Study) about how their study could reveal many more genes\, gene-regulation elements\, and biological pathways that affect ME/CFS risk\, advance efforts to identify new biomarkers for disease subtypes\, and ultimately lead to new treatments. \nRegister for the event here.
URL:https://solvecfs.org/event/sequence-me-long-covid-the-search-for-me-cfs-and-long-covid-biomarkers-and-subtypes/
CATEGORIES:Long Covid,Research,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2026/05/June10DecodeMEFINAL.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260115T090000
DTEND;TZID=America/Los_Angeles:20260115T100000
DTSTAMP:20260715T182111
CREATED:20251028T001815Z
LAST-MODIFIED:20251028T001815Z
UID:42923-1768467600-1768471200@solvecfs.org
SUMMARY:From Mystery to Measurable: The Science Behind the New ME/CFS Blood Test
DESCRIPTION:For the first time\, scientists have developed a simple\, accurate blood test that can potentially identify Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS) — a long-term\, debilitating condition that affects millions of patients worldwide.  \nThe study (published in the Journal of Translational Medicine)\, led by the University of East Anglia in partnership with Oxford BioDynamics\, used cutting-edge 3D genomic technology to look at how DNA is folded inside blood cells. Just like origami\, the shape and folds of DNA control which genes are switched on or off.  \nThe team discovered a distinctive pattern of these folds that appears only in people with ME/CFS — providing a clear biological “fingerprint” of the disease. Using this pattern\, the researchers created a blood test that can diagnose ME/CFS with 96% accuracy. Until now\, doctors have had to rely on symptoms alone and rule out other illnesses\, a process that can take years. This test offers the potential for quicker\, more confident diagnoses and could end the uncertainty many patients face. \nBeyond diagnosis\, the findings also point toward disrupted immune and inflammation pathways\, which may help scientists develop targeted treatments in the future. The same approach could even pave the way for a similar test for Long Covid\, which shares many of the same biological features as ME/CFS. \nThis discovery marks an important turning point: it brings scientific validation to patients whose symptoms have too often been dismissed\, and it opens the door to better understanding\, earlier support\, and more effective care for people living with this complex condition. \nIn this webinar\, Solve CEO Emily Taylor will host research team members Dr. Dmitry Pshezhetskiy (University of East Anglia)\, Dr. Alexandre Akoulitchev\, MA\, PhD\, FRSM (Chief Scientific Officer\, Oxford BioDynamics)\, Bartu Ahiska (Senior Director\, Commercial Development & Marketing Comms\, Oxford BioDynamics)\, and Ewan Hunter (Chief Data and Technology Officer\, Oxford BioDynamics)\, who will discuss the development of their new blood-based assay\, the EpiSwitch CFS test\, and its potential impact on diagnosing and treating people with ME/CFS and Long Covid.
URL:https://solvecfs.org/event/from-mystery-to-measurable-the-science-behind-the-new-me-cfs-blood-test/
CATEGORIES:Long Covid,Research,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2025/10/1.15.26-From-Mystery-to-Measurable.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20251014T150000
DTEND;TZID=America/Los_Angeles:20251014T160000
DTSTAMP:20260715T182111
CREATED:20250814T002133Z
LAST-MODIFIED:20250814T002133Z
UID:42597-1760454000-1760457600@solvecfs.org
SUMMARY:The Unified Platform: Advancing Research Across ME/CFS\, Long Covid\, and Other Chronic Conditions
DESCRIPTION:Chronic illnesses such as myalgic encephalomyelitis (ME) and Long COVID\, which lack clinical biomarkers\, present challenges around diagnosis\, symptom reporting\, and monitoring. That’s why the unhide® Solve Together Unified Platform–which is participant-led with continuous digital data collection–offers some advantages over traditional site-based clinical research models.  \nThe easy-to-use\, secure platform allows patients to contribute data through symptom surveys\, validated assessments\, wearable devices\, and health history to support research across 30+ related conditions. It also uncovers hidden connections between inflammation\, chronic illness\, and overall health.  \nThe Unified Platform enables patients and caregivers to: \n\nTrack symptoms and visualize health patterns over time\nConnect wearable data for more complete insights\nDownload and print customized reports to have better conversations with healthcare providers\nContribute to cross-disease research initiatives\nOptionally receive invitations to participate in clinical trials and studies\nIdentify ways to determine relationships between brain inflammation and mental health symptoms such as brain fog\, difficulty concentrating\, memory issues\, sleep problems\, mood changes\, anxiety\, and depression\n\nParticipants may contribute data across multiple domains: validated surveys (dysautonomia\, PEM\, fatigue\, function)\, daily symptom and treatment logs\, device/sensor data (Apple Watch\, Fitbit\, Garmin)\, and electronic health records (EHRs).  \nIn this webinar\, Solve CEO Emily Taylor\, Brain Inflammation Collaborative (BIC) co-founder and CEO Christy Jagdfeld\, Principal Investigator and lived experience expert Megan L. Fitzgerald\, PhD\, and platform architect and caregiver to a person with ME/CFS Chris Nowak (CareEvolution) will discuss how the unhide® Solve Together Unified Platform facilitates partnerships\, successfully improves patient-provider communication\, enables robust recruitment and multidimensional data collection\, and serves as a catalyst for better health among all who are impacted by neuroinflammation.  \nVisit unhidenow.org to learn more or enroll. \nRegister for the webinar here: https://us02web.zoom.us/webinar/register/WN_ATe5-nbxSsy89D8TcXIInw
URL:https://solvecfs.org/event/the-unified-platform-advancing-research-across-me-cfs-long-covid-and-other-chronic-conditions/
CATEGORIES:Long Covid,Research,Solve Together,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2025/08/UnifiedPlatformWebinar.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20250722T150000
DTEND;TZID=America/Los_Angeles:20250722T160000
DTSTAMP:20260715T182111
CREATED:20250626T213218Z
LAST-MODIFIED:20250626T213218Z
UID:42085-1753196400-1753200000@solvecfs.org
SUMMARY:The ADDRESS-LC Trial: Studying the Impact of Bezisterim on Brain fog and Fatigue in People with Long Covid
DESCRIPTION:In this webinar\, we’ll be joined by panelists Michael Peluso\, MD (Assistant Professor of Medicine\, University of California\, San Francisco) Ezra Spier (Creator\, Long Covid Studies)\, Penelope Markham\, PhD (Senior Vice President\, BioVie) who will discuss the latest updates on Long COVID research and the ADDRESS-LC trial. The ADDRESS-LC trial was designed to assess the potential impact of bezisterim on cognitive impairment/brain fog and fatigue in individuals with Long COVID and is currently recruiting people 18-64 diagnosed with Long Covid. Attendees will learn more about the requirements for participation and how to join the trial. \nIn this discussion led by Solve M.E. President and CEO Emily Taylor\, the panelists will also share how the lived experience of patients has informed the development and conduct of the trial and the importance of patient-researcher collaboration. \nDate:\nTuesday\, July 22\, 2025\nTime:\n3:00 pm PST / 6 pm EST \nRegister here. \n  \n 
URL:https://solvecfs.org/event/the-address-lc-trial-studying-the-impact-of-bezisterim-on-brain-fog-and-fatigue-in-people-with-long-covid/
CATEGORIES:Long Covid,Research
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2025/05/UPDATEDADDRESS-LC.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20250429T150000
DTEND;TZID=America/Los_Angeles:20250429T160000
DTSTAMP:20260715T182111
CREATED:20250407T214650Z
LAST-MODIFIED:20250424T221623Z
UID:41868-1745938800-1745942400@solvecfs.org
SUMMARY:Investigating Immune Dysfunction and T-Cell Exhaustion via Single Cell Immune Profiling in ME/CFS and Long COVID
DESCRIPTION:Join us for a webinar on April 29 from 3-4 pm PT / 6-7 pm ET with Solve Ramsay Research Grant winners Liisa K. Selin\, MD\, PhD\, and Anna Gil\, PhD (viral immunologists from the Univ. of Massachusetts Chan Medical School)\, Roshan Kumar\, PhD (clinical stage global biotech company HiFiBiO Therapeutics)\, and the labs’ patient representatives Megan L. Fitzgerald\, PhD\, and Rivka Solomon\, MS. \nThese two collaborating labs are studying dysregulated immune cells of ME/CFS and Long COVID patients. Their research goals include: gaining insights into the underlying immune mechanisms of these illnesses (including via antigen discovery); better understanding patient subgroups; and finding diagnostic biomarkers and therapeutic innovations. \nThe two labs received funding from the Patient Led Research Collaborative to collaborate on their current project analyzing T cells from ME/CFS and Long COVID patients both functionally and at a single-cell level. \nAlso at this webinar moderated by Solve CEO Emily Taylor\, the Selin Lab will summarize their paper “Identification of CD8 T-cell dysfunction associated with symptoms in ME/CFS and Long COVID and treatment with a nebulized antioxidant/anti-pathogen agent in a retrospective case series.” \nRegistration is free. Sign up here:\nhttps://us02web.zoom.us/webinar/register/WN_mlr1fE3_RdKztSL3JIfSWQ
URL:https://solvecfs.org/event/investigating-immune-dysfunction-and-t-cell-exhaustion-via-single-cell-immune-profiling-in-me-cfs-and-long-covid/
LOCATION:Online
CATEGORIES:Long Covid,Research,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2025/04/SelinGilWebinar.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20241218T100000
DTEND;TZID=America/Los_Angeles:20241218T110000
DTSTAMP:20260715T182111
CREATED:20241111T193438Z
LAST-MODIFIED:20241203T172519Z
UID:41153-1734516000-1734519600@solvecfs.org
SUMMARY:The Future of IACCI and Long Covid Research: ME/CFS and the Unfinished work of the COPVS Task Force
DESCRIPTION:**NEW TIME AND DATE!** \nIn 2021 the National Institutes of Health (NIH) launched the RECOVER Initiative\, a patient-centered\, integrated\, adaptive research network created to study Long Covid. Included in the RECOVER Initiative infrastructure was the Commonalities with Other Post-Viral Syndromes Task Force. \nThe Task Force included Solve President and CEO Emily Taylor\, Dr. Leonard Jason (Professor of Psychology at DePaul University and the Director of the Center for Community Research)\, and other well-known ME/CFS experts and played a crucial role in fostering collaboration among researchers\, clinicians\, and patient advocates. It also facilitated the exchange of knowledge and identified common data elements\, treatment strategies\, and diagnostic criteria. This multidisciplinary approach was essential for advancing our understanding of post-viral illnesses and developing effective interventions. \nThe Task Force concluded that Long Covid researchers can learn from ME/CFS efforts to identify key symptoms\, provide explicit criteria for when a symptom meets the threshold for being considered a problem\, and employ tactics to ensure that consistent information is elicited from patient interviews across settings. \nThe Task Force published a paper on their findings in December 2023 and was then disbanded by NIH. However\, there is clearly still a need to educate care providers\, researchers\, and the public about the connection between ME/CFS and Long Covid. \nIn this webinar\, Emily Taylor and Dr. Jason will discuss their findings and what they signal for the future of research on ME/CFS\, Long Covid\, and other infection-associated chronic conditions and illnesses (IACCIs). The session will conclude with the launch of an important advocacy action.
URL:https://solvecfs.org/event/the-future-of-iacci-and-long-covid-research-me-cfs-and-the-unfinished-work-of-the-copvs-task-force/
CATEGORIES:Advocacy,Long Covid,Research,Solve M.E. Leadership,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2024/11/500LennyJasonCOPVSIG121824.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20241011T090000
DTEND;TZID=America/Los_Angeles:20241011T100000
DTSTAMP:20260715T182111
CREATED:20240918T204343Z
LAST-MODIFIED:20240918T204343Z
UID:40996-1728637200-1728640800@solvecfs.org
SUMMARY:ICUE Webinar: Uniting Voices\, Amplifying Impact: National Organizations Collaborating to Support Our IACC Communities
DESCRIPTION:Please join us for the final\, culminating webinar of the Infection-Associated Chronic Conditions Understanding and Engagement (ICUE) project\, where we will discuss the findings and results from the project as well as on-going efforts to collaborate across the IACC community on advancing awareness\, clinical care\, patient support and research. \nDuring this webinar\, you will hear from ICUE project leadership from the COVID-19 Longhauler Advocacy Project\, Patient-Led Research Collaborative\, and Solve M.E.\, as well as leading experts in IACC education\, clinical care\, and research. At the conclusion of the presentations\, we will take questions and answers. \nThis webinar is an opportunity to learn and identify ways to engage and collaborate. Patients\, clinicians\, researchers\, and various other stakeholders all have vital roles to play\, both independently and collaboratively\, in advancing the understanding and management of IACCs. By working together\, we can raise awareness to advance patient-centered research\, enhance clinical care\, and improve educational outreach\, ultimately leading to better health outcomes for all affected individuals.  \nWe look forward to your participation in this important discussion. Please confirm your attendance by October 10th and join us in our efforts to advance the understanding and management of IACCs. Your involvement is crucial\, and we hope to see you there. \nUNITING VOICES\, AMPLIFYING IMPACT: COLLABORATING TO SUPPORT OUR IACC COMMUNITIES\nFriday\, October 11\, 2024\n9 am PT /12 pm ET \nRegistration link:\nhttps://us06web.zoom.us/webinar/register/WN_JOGSRf0ZQsu0ueVkp2HuWw#/registration \n 
URL:https://solvecfs.org/event/icue-webinar-uniting-voices-amplifying-impact-national-organizations-collaborating-to-support-our-iacc-communities/
CATEGORIES:Advocacy,Long Covid,Research,Solve M.E. Leadership
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2024/09/icue-graphic.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20241003T090000
DTEND;TZID=America/Los_Angeles:20241003T100000
DTSTAMP:20260715T182111
CREATED:20240923T183251Z
LAST-MODIFIED:20240923T183251Z
UID:40947-1727946000-1727949600@solvecfs.org
SUMMARY:Skeletal Muscle Fatigue and Post-Exertional Malaise in Patients with Long Covid and Implications for ME/CFS
DESCRIPTION:On Thursday\, October 3\, 2024\, Solve M.E. will host a free educational webinar featuring Assistant Professor Rob Wüst from the Vrije Universiteit (Amsterdam\, Netherlands)\, who will discuss skeletal muscle fatigue and post-exertional malaise in patients with Long Covid and the implications for ME/CFS. \nDr. Wüst received a Solve M.E. Ramsay Research Grant in 2022 to study muscle pain\, post-exertional malaise\, and treatments for pain and malaise in patients with diseases like Long Covid and ME/CFS. He found that\, at the physiological and molecular levels\, post-exertional malaise differs from general fatigue. These differences have big implications for how physical therapy affects patients with Long Covid or ME/CFS. \nDr. Wüst will update us on his studies of these two central symptoms of Long Covid and ME/CFS—post-exertional malaise and general fatigue and answer questions from attendees. \nTime: 9 am PT / 12 pm ET \nDate: Thursday\, October 3 \nRegister here: https://us02web.zoom.us/webinar/register/WN_LRCE4Xg9SWa2dpWppLHJwg \n*The content provided by Solve M.E. in this webinar is for informational purposes only and does not constitute legal or medical advice. Viewers are encouraged to consult with qualified legal or medical professionals for specific advice tailored to their individual circumstances.*
URL:https://solvecfs.org/event/skeletal-muscle-fatigue-and-post-exertional-malaise-in-patients-with-long-covid-and-implications-for-me-cfs/
CATEGORIES:Long Covid,Research,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2024/09/WustWebinar.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20240910T120000
DTEND;TZID=America/Los_Angeles:20240910T130000
DTSTAMP:20260715T182111
CREATED:20240724T232700Z
LAST-MODIFIED:20240724T232804Z
UID:40840-1725969600-1725973200@solvecfs.org
SUMMARY:Solve Author Series:  Dr. Peter Rowe Discusses "Living Well with Orthostatic Intolerance: A Guide to Diagnosis and Treatment"
DESCRIPTION:Orthostatic intolerance (OI) describes a group of circulatory disorders whose symptoms are characterized by a dramatic drop in blood flow to the brain when people are sitting for long periods or standing still. It is often associated with other acute issues\, such as substantial drops in blood pressure\, tachycardia\, dizziness\, fainting\, or other long-term problems\, including ME/CFS and Long Covid.  \nIn his new book\, Living Well with Orthostatic Intolerance: A Guide to Diagnosis and Treatment\, Peter Rowe\, MD\, (Director of the Chronic Fatigue Clinic at Johns Hopkins Children’s Center and member of Solve M.E.’s Research Advisory Council) provides an overview of OI and its causes\, diagnosis\, symptom management and more.  \nIn this installment of our author spotlight series\, Solve President and CEO Emily Taylor talks to Dr. Rowe about his indispensable new guide for those diagnosed with the disorder\, their families\, and physicians. \nGuided by decades of research on managing and treating OI patients\, Dr. Rowe will provide illustrative case studies to help explain the disease and answer questions from attendees. \nPurchase a copy of Living Well with Orthostatic Intolerance: A Guide to Diagnosis and Treatment via Johns Hopkins University Press or Amazon. \nTuesday\, September 10\, 2024\n12-1 pm PT / 3-4 pm ET\nRegister here:\nhttps://us02web.zoom.us/webinar/register/WN_8pUWIfiqSvaL_d8gByvbUg
URL:https://solvecfs.org/event/solve-author-series-dr-peter-rowe-discusses-living-well-with-orthostatic-intolerance-a-guide-to-diagnosis-and-treatment/
CATEGORIES:Long Covid,Research,Solve M.E. Leadership,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2024/07/Rowe-Webinar-Sept.-2024-IG-500.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20240702T130000
DTEND;TZID=America/Los_Angeles:20240702T140000
DTSTAMP:20260715T182111
CREATED:20240612T232500Z
LAST-MODIFIED:20240624T163929Z
UID:40591-1719925200-1719928800@solvecfs.org
SUMMARY:Covid Vaccinations: Efficacy\, Options\, and Special Considerations for Chronic Illness
DESCRIPTION:People with chronic illnesses often have compromised immune systems or ongoing health issues that can affect how they respond to vaccines. The effectiveness and potential side effects of vaccines may differ for these individuals compared to the general population. Individuals with chronic illnesses may be at a higher risk of experiencing adverse reactions to vaccines. This can make them hesitant to receive the vaccine and necessitates a careful evaluation of risks and benefits. \nTo help inform our community\, Solve is hosting the free webinar\, “Covid Vaccinations: Efficacy\, Options\, and Special Considerations for Chronic Illness.” Solve President & CEO Emily Taylor and Solve Chief Scientific Officer H. Tim Hsiao\, PhD. will talk to infectious disease epidemiologist and science communicator Jessica Malaty Rivera\, M.S. (Chair\, Committee of Scientific and Medical Advisors\, Vaccinate Your Family) and distinguished physician Melanie Hoppers\, M.D. (Medical Provider\, Bateman Horne Center) about the complex issues surrounding Covid vaccination for those with ME/CFS\, Long Covid\, and other infection-associated chronic conditions and illnesses. \nThis comprehensive session will delve into: \n• The effectiveness of Covid vaccinations in preventing Long Covid and other long-term symptoms.\n• An overview of the different types of Covid vaccines currently available.\n• Insights into how vaccine manufacturers address the special needs of individuals with chronic illnesses during vaccine development.\n• Expert advice on how people with ME/CFS\, Long Covid\, and other infection-associated chronic conditions can make informed decisions about Covid vaccination. \nOur experts will provide valuable information\, answer your questions\, and offer practical guidance tailored to those with chronic health conditions. Don’t miss this opportunity to gain clarity and confidence in your vaccination choices. \nThis event is funded in part by an educational grant from Novavax. \nRegister here:\nhttps://us02web.zoom.us/webinar/register/WN_-vcECdI4QImGHEJpSJOo-Q
URL:https://solvecfs.org/event/covid-vaccinations-efficacy-options-and-special-considerations-for-chronic-illness/
CATEGORIES:Long Covid,Research,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2024/06/CovidVaccinationsWebinar.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20240508T123000
DTEND;TZID=America/Los_Angeles:20240508T133000
DTSTAMP:20260715T182111
CREATED:20240409T224442Z
LAST-MODIFIED:20240507T205214Z
UID:40225-1715171400-1715175000@solvecfs.org
SUMMARY:Comparing immunological signatures between Long Covid and ME/CFS
DESCRIPTION:**Webinar date changed to May 8\, 2024** \nDr. David Putrino and Dr. Jamie Wood\, of the Icahn School of Medicine at Mount Sinai\, have conducted several landmark studies on Long Covid. Their extensive research has led them to suspect that the immune responses of people with Long Covid differ in important ways from the immune responses of other people. If so\, these differences (called immunological signatures) may explain why some people develop Long Covid symptoms and hopefully lead to the development of new therapies. To find this information\, the team uses a wide range of cutting-edge technologies to compare blood and saliva samples from people with Long Covid with those from healthy participants. \nBecause both Long Covid and ME/CFS are post-acute infection syndromes (and have similar symptoms)\, the team also wants help from people with ME/CFS to find immunological signatures for ME/CFS. Similarities between the ME/CFS and Long Covid signatures may lead to therapeutic options for anyone with a post-acute-infection syndrome. \nIn this webinar\, Dr. Putrino and Dr. Wood will explain their ongoing research and the current study\, which has high potential to generate new knowledge and to help people diagnosed with ME/CFS or other post-acute infection syndromes. \nRegister here: https://us02web.zoom.us/webinar/register/WN_GY4b1ezER7udraoDjGTD8g \nThe Solve Together Real-World Data Platform (ST-RWD) will soon begin to refer consented ST-RWD users who have relevant profiles to be considered for participating in this study that compares ME/CFS and Long Covid. If you are interested\, please consider joining ST-RWD via https://solvecfs.org/research/solve-together/ by April 30\, 2024. You can also email us at research@solvecfs.org if you have any questions.
URL:https://solvecfs.org/event/comparing-immunological-signatures-between-long-covid-and-me-cfs/
CATEGORIES:Long Covid,Research,Solve Together
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2024/04/MAY-8-Putrino-Webinar-IG.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20240429T130000
DTEND;TZID=America/Los_Angeles:20240429T140000
DTSTAMP:20260715T182111
CREATED:20240409T175152Z
LAST-MODIFIED:20240430T005000Z
UID:40219-1714395600-1714399200@solvecfs.org
SUMMARY:Symptom Management and Patient Empowerment Through The Long Covid Wearable Study
DESCRIPTION:The lived experiences of people with ME and Long Covid have shown that activity management\, or pacing\, can be an effective method of reducing symptom severity. However\, pacing is difficult to implement. Many people living with energy-limiting conditions have utilized wrist-worn wearables\, or activity trackers\, to help implement pacing. To validate the value of using wearables to implement pacing\, Scripps Research is launching The Long Covid Wearable Study. This one-year study will gather survey and wearable data in a bid to better manage symptoms and empower study participants to manage their health. \nIn this webinar\, Julia Moore Vogel\, PhD\, (Senior Program Director at Scripps Research and Principal Investigator of the Long Covid Wearable Study) will share more details on the study (including the inclusion criteria)\, explain how you can join the study using your Solve Together account\, and answer questions from attendees. \nIf you are enrolled in the Solve Together Real-World Data Platform (ST-RWD)\, you can easily join this study based on your ST-RWD account. We will send relevant instructions through the ST-RWD platform messaging system by May 6th\, 2024\, on how to join this study directly from your ST-RWD dashboard. \nIf you are not a current user of the Solve Together RWD Platform\, you can learn more about what the platform has to offer on this webpage (https://solvecfs.org/research/solve-together/). You can also email us at research@solvecfs.org if you have any questions. \nWatch a recording of the webinar here:
URL:https://solvecfs.org/event/symptom-management-and-patient-empowerment-through-the-long-covid-wearable-study/
CATEGORIES:Long Covid,Research,Solve Together,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2024/04/Scripps-Webinar-IG.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20240122T130000
DTEND;TZID=UTC:20240122T140000
DTSTAMP:20260715T182111
CREATED:20240109T015707Z
LAST-MODIFIED:20240116T233355Z
UID:39715-1705928400-1705932000@solvecfs.org
SUMMARY:Changes in the Gut Microbiome in ME/CFS and Long Covid
DESCRIPTION:Solve Ramsay Research Grant winner David Esteban\, PhD\, (Assoc. Professor of Biology\, Vassar College) will discuss ongoing work in his lab determining whether there is a link between changes in the gut microbiome and disease in ME/CFS and Long Covid. The collection of bacteria in the gut\, known as the gut microbiome\, produces many small molecules that can affect the immune\, nervous\, and gastrointestinal systems. In several other diseases\, microbial products of the amino acid tryptophan have been linked to symptoms or disease severity. \nIn this webinar\, Esteban will discuss his work to measure the amounts and activity of these important molecules in people with ME/CFS and Long Covid. Recruitment for Dr. Esteban’s study is being conducted on the Solve Together platform\, for more information or to join\, visit SolveTogether.org or email us at research@solvecfs.org. \nThis event is funded in part by an educational grant from Novavax.
URL:https://solvecfs.org/event/changes-in-the-gut-microbiome-in-me-cfs-and-long-covid/
CATEGORIES:Long Covid,Research,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2024/01/Jan-22-Gut-Microbiome-Final_500.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20231207T120000
DTEND;TZID=America/Los_Angeles:20231207T130000
DTSTAMP:20260715T182111
CREATED:20231114T164759Z
LAST-MODIFIED:20231122T145559Z
UID:39491-1701950400-1701954000@solvecfs.org
SUMMARY:The Patient-Doctor Partnership: Optimally Treating People with Long Covid and ME/CFS Across the US
DESCRIPTION:Solve welcomes three medical providers who will share their experience with treating Long Covid\, ME/CFS\, POTS\, and dysautonomia patients across rural\, urban\, and suburban settings. Dr. Melanie Hoppers (co-founder and Chief Medical Officer at Physicians Quality Care\, in Jackson\, TN)\, Dr. William Pittman (co-director of the UCLA Long COVID Program)\, and Dr. Tiffany Walker (Principal Investigator for the Post-COVID Clinic Grady Hospital\, Emory University School of Medicine) will share how integrating a broader understanding of associated post-infection diseases has informed their care\, and offer insights into how patients and caregivers can best work together to create an optimal treatment experience. \n  \nThis event is funded in part by an educational grant from Novavax.
URL:https://solvecfs.org/event/the-patient-doctor-partnership-optimally-treating-people-with-long-covid-and-me-cfs-across-the-us/
CATEGORIES:Long Covid,Research,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2023/11/dec-7-webinar.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20230926T110000
DTEND;TZID=America/Los_Angeles:20230926T120000
DTSTAMP:20260715T182111
CREATED:20230815T233137Z
LAST-MODIFIED:20230918T181956Z
UID:39065-1695726000-1695729600@solvecfs.org
SUMMARY:Federal Policy: How to Make an Impact with Support Long COVID and a National Taskforce
DESCRIPTION:Join Solve M.E.\, Marked By Covid\, and Long COVID Alliance for an interactive discussion on key COVID policy actions: the National Task Force on the COVID-19 Pandemic Act (S.1489) and Long COVID Support Act (S.2560). This event will detail the bills\, their importance for the COVID and Long Covid patient community\, and next steps for federal advocacy in 2024.  \nSee Samantha Koehler (Health Policy Advisor\, Sen. Tim Kaine) and Gilbert Ruiz (Legislative Director\, Sen. Kirsten Gillibrand) in conversation with Kristin Urquiza (Co-founder\, Marked By Covid)\, Emily Taylor (Vice President of Advocacy\, Solve M.E.)\, Liza Fisher (Executive Committee Member\, Long COVID Alliance)\, and Michael Sieverts (Executive Committee Member\, Long COVID Alliance).  \nRegister here.
URL:https://solvecfs.org/event/advocacy-cafe-chat-2/
LOCATION:Online
CATEGORIES:Advocacy,Long Covid
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2023/08/LC-Federal-Policy-Webinar-Updated.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20230427T110000
DTEND;TZID=America/Los_Angeles:20230427T120000
DTSTAMP:20260715T182111
CREATED:20230405T221942Z
LAST-MODIFIED:20230405T222038Z
UID:38161-1682593200-1682596800@solvecfs.org
SUMMARY:Effects of Long Covid and ME/CFS on Sleep
DESCRIPTION:Many individuals who have had COVID-19 experience long-term symptoms that have a major impact on their lives. One of the most common symptoms is sleep disturbance. After more than six months from the time of infection\, about 60% of people self-report lingering sleep difficulties\, even if they had a mild course of acute COVID-19. Unrefreshing sleep is also part of the diagnostic criteria for ME/CFS\, along with other overlapping symptoms such as post-exertional malaise (PEM) or “brain fog.” \nTo probe deeper into the topic of sleep\, we are pleased to invite you to a webinar on the Effects of Long Covid and ME/CFS on Sleep\, featuring  SleepScore Lab’s neuroscientist\, Dr. Elie Gottlieb. The presentation will cover a range of topics including: \n\nThe connection between Long Covid\, ME/CFS\, and sleep disturbances.\nThe neurological and cognitive aspects of sleep and how brain changes/disruptions may be bi-directionally associated with Long Covid and ME/CFS.\nUnrefreshing sleep vs. quality sleep and why people with ME/CFS or Long COVID might experience the former.\nThe evidence-based methods to improve sleep and how SleepScore Lab’s improvement program addresses them.\n\n The presentation will be followed by a live Q&A. \nRegister here.
URL:https://solvecfs.org/event/effects-of-long-covid-and-me-cfs-on-sleep/
LOCATION:Online
CATEGORIES:Long Covid,Research,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2023/04/April-27-Sleepscore-webinar.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20230425T100000
DTEND;TZID=America/New_York:20230425T160000
DTSTAMP:20260715T182111
CREATED:20230301T234226Z
LAST-MODIFIED:20230301T234226Z
UID:37888-1682416800-1682438400@solvecfs.org
SUMMARY:FDA Patient-Focused Drug Development Public Meeting for Long Covid
DESCRIPTION:The US Food and Drug Administration (FDA) is hosting a virtual public meeting on Patient-Focused Drug Development for Long Covid on Tuesday\, April 25th\, 2023\, from 10 a.m. to 4:00 p.m. ET.  It will be conducted with live translation in both English and Spanish. \nPatient-Focused Drug Development meetings are important and infrequent opportunities for patients to provide direct input to the FDA\, as well as for the FDA to obtain patient and patient representative input on several aspects related to a disease. ME/CFS was one of the earliest diseases to benefit from the concept of including patients in this process\, approximately a decade ago. \nThis meeting will focus on Long Covid\, how it affects daily life\, symptoms that matter most to patients\, current approaches to treating Long Covid\, and considerations for clinical trial participation. \nSolve M.E. encourages individuals in our community with Long Covid\, family members\, advocates\, caregivers\, and other stakeholders to participate in the live webcast. Register here and find more information on the discussion questions and meeting format\, and find more information on FDA’s website. \nPatients or caregivers who are willing to share their experiences as part of a panel conversation are asked to indicate their willingness as part of registration. They will then be directed to send a short summary of their responses to the discussion questions to PatientFocused@fda.hhs.gov.
URL:https://solvecfs.org/event/fda-patient-focused-drug-development-public-meeting-for-long-covid/
LOCATION:Online
CATEGORIES:Long Covid,Research
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2023/03/Untitled-design-4.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20230330T110000
DTEND;TZID=America/Los_Angeles:20230330T120000
DTSTAMP:20260715T182111
CREATED:20230316T000937Z
LAST-MODIFIED:20230321T200001Z
UID:38021-1680174000-1680177600@solvecfs.org
SUMMARY:How to Make an Impact at the FDA's Drug Development Meeting for Long Covid
DESCRIPTION:On April 25th\, 2023\, FDA is hosting a virtual public meeting on Patient-Focused Drug Development (PFDD) for Long Covid. This meeting will provide FDA the opportunity to obtain initial patient and patient representative input on the aspects of Long Covid\, including how Long COVID affects their daily life\, the symptoms that matter most to patients\, their current approaches to treating Long Covid\, and what they consider when determining whether or not to participate in a clinical trial. \n\n\n\n\nAhead of the FDA’s PFDD for Long Covid\, Solve M.E. will host a webinar on March 30th from 11- 12 pm PT / 2-3pm ET to help educate our community about this important event. \nThis is a unique opportunity to share stories of living with Long Covid\, as well as experiences with treatments\, with important decision-makers at the FDA. Though Solve is not involved in the planning of the PFDD meeting\, we have invited two former FDA officials who are experts in this area to help prepare our community for this important day. \n\nJames Valentine\, JD\, MHS\, has worked the last 15 years as a champion for the patient voice as part of the regulatory process.  James previously worked at the FDA where he was a patient liaison\, helping to incorporate the patient voice into medical product review across the FDA’s various medical product centers and review divisions.  There\, he helped to develop and launch the Patient-Focused Drug Development initiative.\nLarry Bauer\, RN\, MS\, worked at the NIH for 17 years in clinical research\, followed by a position at the FDA as a Regulatory Scientist in the Center for Drug Evaluation and Research’s Rare Diseases Program\, a group he co-founded and worked for 10 years\, where he advanced rare disease drug development. In private practice\, James and Larry have worked with many patient organizations to ensure their community’s voices were heard by decision-makers.  Relevant to the upcoming PFDD meeting\, both Larry and James were involved in these FDA-led PFDD meetings in their time at the Agency\, and since leaving have been a resource to the majority of patient communities participating in FDA’s sister externally-led PFDD program.\n\nThe hoped outcome of the meeting is to improve the development of new drugs in the research pipeline and inform the context in which regulatory decisions will be made for new drugs for Long Covid. \nDuring the webinar on March 30th\, we will be covering the following topics: \n\nBackground on FDA & Drug Development\nIntroduction to Patient-Focused Drug Development & Role of Patient Voice\nOverview of the PFDD Meeting\nGuide to Participating in the Meeting\nLogistics\, Format\, & Tips\n\nIt doesn’t matter where you live or where you are in your journey\, what matters is your story. \nRegister here.
URL:https://solvecfs.org/event/how-to-make-an-impact-at-the-fdas-drug-development-meeting-for-long-covid/
LOCATION:Online
CATEGORIES:Long Covid,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2023/03/Webinars-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20230329T100000
DTEND;TZID=America/Los_Angeles:20230329T110000
DTSTAMP:20260715T182111
CREATED:20230228T040819Z
LAST-MODIFIED:20230301T004824Z
UID:37834-1680084000-1680087600@solvecfs.org
SUMMARY:CDC Update: Recent Strides in Long Covid
DESCRIPTION:In this webinar\, Solve M.E. President Oved Amitay welcomes Dr. Elizabeth Unger\, chief of Chronic Viral Diseases Branch at Centers for Disease Control and Prevention\, and her CDC colleagues to share updates and progress on The School-Based Active Surveillance Project (presented by Anindita Nanda Issa\, MD)\, the Long Covid Fatiguing Illness Recovery Program (ECHO) (presented by Jennifer Cope\, MD\, MPH)\, and initial findings from the Multi-site Study of Post-COVID conditions (Medical chart abstraction project) (presented by Miriam Nji\, MD\, MPH). \nRegister here.
URL:https://solvecfs.org/event/cdc-update-recent-strides-in-long-covid/
LOCATION:Online
CATEGORIES:Long Covid,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2023/02/CDC-Webinar-Updated-Graphic.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Asia/Shanghai:20230221T100000
DTEND;TZID=Asia/Shanghai:20230221T130000
DTSTAMP:20260715T182111
CREATED:20230131T184624Z
LAST-MODIFIED:20230216T234324Z
UID:37499-1676973600-1676984400@solvecfs.org
SUMMARY:Solve M.E. and BIO co-host "Long Covid: What Will It Take To Accelerate Therapeutic Progress?"
DESCRIPTION:Solve M.E. and The Biotechnology Innovation Organization (BIO) will co-host a three-hour virtual event “Long Covid: What Will It Take to Accelerate Therapeutic Progress?” on Tuesday\, February 21 from 10:00 AM – 1:00 PM PT (1:00 – 4:00 PM ET).  \nOur goal is to convene stakeholders to advance research and development to diagnose and treat Long Covid\, ME/CFS\, and other post-infection diseases. By increasing awareness among drug developers to the unmet needs of our communities\, we hope to inspire these industry players to study these diseases and create therapeutic breakthroughs.  \nThe session will establish a knowledge base of emerging research in Long Covid and existing body of data in other post-infection diseases (such as myalgic encephalomyelitis/chronic fatigue syndrome\, dysautonomia\, mast cell activation\, and others). The session also will feature solution-oriented perspectives from government\, academic\, and industry researchers\, patient groups\, funding sources\, and policymakers.  \nHosts: \n\nOved Amitay\, R.Ph.\, M.Sc.\, President and CEO of Solve M.E. Christopher Austin\, MD\, CEO-Partner\, Flagship Pioneering\nCartier Esham\, PhD\, Chief Science Officer\, Biotechnology Innovation Organization (BIO)\n\nOpening Remarks: \n\nUS Senator\, Tim Kaine\nRachel L. Levine\, M.D.\, Admiral\, U.S. Public Health Service\, U.S. Department of Health and Human Services\n\nSpeakers: \n\nAkiko Iwasaki\, PhD\, Sterling Professor of Immunobiology (Microbial Diseases)\, Yale School of Medicine\nBruce Patterson\, MD\, CEO & Founder\, IncellDx\nChristopher Austin\, MD\, CEO-Partner\, Flagship Pioneering\nDavid Putrino\, PhD\, Associate Professor\, Rehabilitation and Human\nJulie Gerberding\, MD\, MPH\, CEO\, Foundation for the National Institutes of Health\nKatie Bach\, MBA\, Nonresident Senior Fellow\,Brookings Institution\nLisa McCorkell\, MPP\, Co-Founder\, Patient-Led Research Collaborative\nMargaret Koziel\, MD\, SVP\, Chief Medical Officer\, Axcella Therapeutics\nPriti Patel\, MD\, MPH\, Senior Advisor for Post-COVID Conditions\, Centers for Disease Control and Prevention\nRachel L. Levine\, M.D.\, Admiral\, U.S. Public Health Service\, U.S. Department of Health and Human Services\nSeth Lederman\, MD\, Co-Founder\, CEO & Chairman\, Tonix Pharmaceuticals\nThomas Equels\, M.S.\, J.D.\, CEO\, AIM Immunotech\nWalter Koroshetz\, MD\, Director\, National Institute of Neurological Disorders and Stroke (NINDS)\n\nSolve M.E. is a non-profit organization that serves as a catalyst for critical research into diagnostics\, treatments\, and cures for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)\, Long Covid and other post-infection diseases.  \nBIO is the world’s largest advocacy association representing member companies\, state biotechnology groups\, academic and research institutions\, and related organizations across the United States and in 30+ countries.
URL:https://solvecfs.org/event/solve-m-e-and-bio-co-host-long-covid-what-will-it-take-to-accelerate-therapeutic-progress/
CATEGORIES:Long Covid,Research,Solve M.E. Leadership,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2023/01/Sample-Bio-Graphic.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20221220T100000
DTEND;TZID=America/Los_Angeles:20221220T110000
DTSTAMP:20260715T182111
CREATED:20221214T003117Z
LAST-MODIFIED:20221214T003117Z
UID:37305-1671530400-1671534000@solvecfs.org
SUMMARY:Long COVID Technology
DESCRIPTION:As we approach the end of the year\, we are also wrapping up a stellar\, year-long webinar partnership with the Global Interdependence Center that has explored the pandemic’s long-term healthcare\, policy\, and economic impact\, specifically the implications of Long Covid. \nThe final installment in the series\, “Long Covid Technology\,” will take place on December 20. This webinar will explore the impacts technology has had on Long Covid developments with speaker Amy Proal\, Ph.D.\, Microbiologist/Research Team Coordinator at PolyBio Research Foundation\, Miguel Antonatos\, MD\, founder of Text2Med\, Harry Leeming\, founder of Visible\, and Andrew Rosenberg\, founder of Responsum Health. \n \nRegister here.
URL:https://solvecfs.org/event/long-covid-technology/
CATEGORIES:Long Covid,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2022/03/Webinars.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20221215T100000
DTEND;TZID=America/Los_Angeles:20221215T110000
DTSTAMP:20260715T182111
CREATED:20221102T213657Z
LAST-MODIFIED:20221213T200457Z
UID:36932-1671098400-1671102000@solvecfs.org
SUMMARY:Challenges in Ensuring Equity In the Study and Treatment of ME/CFS and Long Covid
DESCRIPTION:Co-presented by Peter Rowe\, MD (Professor of Pediatrics\, Director\, Johns Hopkins Children’s Center Chronic Fatigue Clinic) and Camille Broussard\, MD\, MPH (Assistant Professor in the Division of Adolescent and Young Adult Medicine at Johns Hopkins School of Medicine)\, this webinar will explore the dissonant results of epidemiologic studies that suggest Latinx and Black individuals have a higher risk of ME/CFS and Long Covid than Whites\, while ME/CFS and Long Covid clinic populations in different countries are disproportionately composed of White individuals. We will look at the course of one young Black ME/CFS patient\, Jailyn Mercadel\, RN\, and hear from her about her experiences with the healthcare system. Dr. Broussard will then lead a discussion of the possible causes of the dissonant clinical and epidemiological findings\, and make suggestions for a more equitable approach to studies and clinical care. \nRegister here.
URL:https://solvecfs.org/event/challenges-in-ensuring-equity-in-the-study-and-treatment-of-me-cfs-and-long-covid/
LOCATION:Online
CATEGORIES:Long Covid,Research,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2022/11/RoweBroussard-Webinar.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20221129T100000
DTEND;TZID=America/Los_Angeles:20221129T110000
DTSTAMP:20260715T182111
CREATED:20221102T210847Z
LAST-MODIFIED:20221102T210847Z
UID:36930-1669716000-1669719600@solvecfs.org
SUMMARY:Long Covid in the Media
DESCRIPTION:Solve M.E. is continuing our event series with the Global Interdependence Center with a panel on November 29 10AM PT.  \nThe sixth installment of the GIC Solve Long Covid Initiative Program Series will explore the impact and coverage of Long Covid in the media. Join us virtually with speakers\, Cynthia Adinig\, Long Covid Advocate and Equity Policy Advisor\, Sandhya Kambhampati\, data reporter on the Los Angeles Times Data Desk\, and Fiona Lowenstein\, Founder of Body Politic. This event will also feature Meghan O’Rourke\, author of the New York Times bestseller “The Invisible Kingdom: Reimagining Chronic Illness.”
URL:https://solvecfs.org/event/long-covid-in-the-media/
LOCATION:Online
CATEGORIES:Long Covid,Media,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2022/03/Webinars.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20221108T090000
DTEND;TZID=America/Los_Angeles:20221108T103000
DTSTAMP:20260715T182111
CREATED:20221102T204439Z
LAST-MODIFIED:20221102T204639Z
UID:36927-1667898000-1667903400@solvecfs.org
SUMMARY:Understanding the Biomarkers of PASC (otherwise known as Long Covid)
DESCRIPTION:The RECOVER Research Review (R3) Seminar Series will host a panel discussion titled\, “Understanding the Biomarkers of PASC” on Tuesday\, November 8th 12:00-1:30 PM EDT featuring: \n\nMichael Peluso\, MD\, University of California\, San Francisco\nMohamed Abdel-Mohsen\, PhD\, The Wistar Institute\nDavid R. Walt\, PhD\, Harvard Medical School; Brigham and Women’s Hospital \nGrace McComsey\, MD\, University Hospitals Health System; Case Western Reserve University \n\n\nThe goal of the R3 Seminar Series is to catalyze a shared understanding of the research of the scientific stakeholder community\, keep researchers up to date on insights and discoveries\, and inform the public about RECOVER and other research on PASC (otherwise known as Post-Covid or Long Covid).\n \nRegister here.
URL:https://solvecfs.org/event/understanding-the-biomarkers-of-pasc-otherwise-known-as-long-covid/
LOCATION:Online
CATEGORIES:Long Covid,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2022/11/Recover-118.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20221024T100000
DTEND;TZID=America/Los_Angeles:20221024T110000
DTSTAMP:20260715T182111
CREATED:20220908T180809Z
LAST-MODIFIED:20220908T190616Z
UID:36345-1666605600-1666609200@solvecfs.org
SUMMARY:COVID-19 as a Trigger for ME/CFS: Severity Biomarkers and Underlying Mechanisms
DESCRIPTION:Since the beginning of the pandemic\, SARS-CoV-2 has been suspected of causing chronic fatigue syndrome (ME/CFS). A well-controlled cohort study conducted by a group of researchers from Charité – Universitätsmedizin Berlin and the Max Delbrück Center for Molecular Medicine (MDC) has now shown that in the subset of patients who suffer from fatigue and exertion intolerance after mild-COVID-19\, around half of patients meet the diagnostic criteria for ME/CFS. \nTheir findings also describe differences between post-COVID ME/CFS patients and ME/CFS patients in the correlation between hand grip strength and inflammatory biomarkers. This may indicate differences in underlying mechanisms. The researchers’ findings have been published in Nature Communications. \nIn this webinar\, Prof. Dr. Carmen Scheibenbogen (Acting Director of Charité’s Institute of Medical Immunology on Campus Virchow-Klinikum and Solve M.E. Ramsay Research Grant awardee) will discuss the findings of this study\, and how the new findings may help researchers to develop specific treatments for post-Covid ME/CFS and ME/CFS. \nRegister here.
URL:https://solvecfs.org/event/covid-19-as-a-trigger-for-me-cfs-severity-biomarkers-and-underlying-mechanisms/
LOCATION:Online
CATEGORIES:Long Covid,Research,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2022/09/Carmen-S-Webinar.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20221013T120000
DTEND;TZID=America/Los_Angeles:20221013T130000
DTSTAMP:20260715T182111
CREATED:20220927T171943Z
LAST-MODIFIED:20220927T171943Z
UID:36420-1665662400-1665666000@solvecfs.org
SUMMARY:Long Covid & Fatiguing Illness Recovery Program
DESCRIPTION:Research Update \nFeaturing: \n\nAvindra Nath\, MD (Clinical Director of National Institute of Neurological Disorders and Stroke – NIH; Chief of the Section of Infections of the Nervous System – NIH; Director of the Translational Neuroscience Center – NIH) Article: https://academic.oup.com/brain/article/145/7/2555/6621999\nHector Bonilla\, MD (Associate Professor of Medicine and Infectious Diseases – Stanford University Medical Director – ME/CFS Clinic – Stanford University) Article: https://pubmed.ncbi.nlm.nih.gov/35195253/\nAnna Nordvig\, MD (Assistant Professor of Neurology and Neuroscience – New York Presbyterian/ Weill Cornell Memory Disorders Program) Article: https://academic.oup.com/brain/advance-article/doi/10.1093/brain/awac270/6672950\nPanelist: Michelle Haddad\, PhD\n\nA CDC-funded monthly webinar-style ECHO learning session to rapidly disseminate Post-acute Sequelae of COVID-19 (PASC) and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) findings and emerging best practices. \nRegister here.
URL:https://solvecfs.org/event/long-covid-fatiguing-illness-recovery-program-3/
LOCATION:Online
CATEGORIES:Long Covid,Research,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2022/09/Echo-1013.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221007
DTEND;VALUE=DATE:20221009
DTSTAMP:20260715T182111
CREATED:20220829T205323Z
LAST-MODIFIED:20220829T205415Z
UID:36247-1665100800-1665273599@solvecfs.org
SUMMARY:ME/CFS + Long Covid International Conference 2022
DESCRIPTION:The Finnish Association of Orthopaedic Manual Therapy (FIAOMT) is hostng an international conference of ME/CFS and Long Covid – Treatment and Rehabilitation is held in Tampere Finland (also online) on 7-8 October 2022. The conference presents current information about ME/CFS and Long Covid. \nThis two-day conference will review the challenges of understanding the pathophysiology\, risk factors\, clinical presentation\, treatment and rehabilitation of post COVID-19 condition (Long COVID) and ME/CFS (myalgic encephalomyelitis/ chronic fatigue syndrome). Bringing together top researchers\, clinicians and therapists working in this field we can better understand the underlying mechanisms and identify potential treatments. \nLearn more here.
URL:https://solvecfs.org/event/me-cfs-long-covid-international-conference-2022/
LOCATION:Online
CATEGORIES:Long Covid,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2022/08/Hoito-ja-kuntoutus-MECFS-Long-COVID9.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221003
DTEND;VALUE=DATE:20221004
DTSTAMP:20260715T182111
CREATED:20220906T221240Z
LAST-MODIFIED:20220906T221240Z
UID:36340-1664755200-1664841599@solvecfs.org
SUMMARY:Long Covid Stakeholder Meeting
DESCRIPTION:The National Center for Health Research is hosting a national conference on October 3 featuring Long Covid healthcare professionals and patient advocates about effective treatments and interventions for Long Covid\, as well as research that is needed or underway. \nSpeakers and panel discussions will include topics such as autoimmune diseases\, challenges for caregivers\, overlap of Long Covid and ME/CFS\, Long Covid in children\, and the role of VA medical centers\, among others. \nPlease register by emailing Ashley at info@center4research.org. Please indicate if you are planning to attend a) in person or b) remotely\, and if in-person if you would like to request travel funds.
URL:https://solvecfs.org/event/long-covid-stakeholder-meeting/
LOCATION:Online
CATEGORIES:Conference,Long Covid
ATTACH;FMTTYPE=image/jpeg:https://solvecfs.org/wp-content/uploads/2022/09/Oct-3-LC-Conference.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20220921T080000
DTEND;TZID=America/Los_Angeles:20220921T150000
DTSTAMP:20260715T182111
CREATED:20220912T183613Z
LAST-MODIFIED:20220912T183631Z
UID:36349-1663747200-1663772400@solvecfs.org
SUMMARY:Aila Health Presents Free Virtual Long Covid Summit
DESCRIPTION:Our friends at Aila Health are hosting a free Long Covid Summit on Wednesday\, September 21 8 AM – 3 PM PT to bring together specialists\, longhaulers\, caregivers\, advocacy organizations\, researchers and health system leaders to shed light on invisible illness and why Long Covid needs more attention. \nSolve M.E. Vice President of Advocacy and Engagement Emily Taylor will join to present Long Covid Advocacy and Policy. \nLearn more and register here.
URL:https://solvecfs.org/event/aila-health-presents-free-virtual-long-covid-summit/
LOCATION:Online
CATEGORIES:Conference,Long Covid
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2022/09/Long-Covid-Summit_Shareable-Posts.png
END:VEVENT
END:VCALENDAR